NTLA

#2074
Intellia Therapeutics, Inc
14.7800 USD
+3.65%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
14.7800
14.7800
Rango anual
7.9500
17.0900
Cambio diario
+3.65%
Variación mensual
+12.65%
Variación en los últimos 6 meses
+7.73%
Cambio anual
+7.73%
Cierres anteriores
14.2600
Abrir
14.7800
Bid
Ask
Mínimo
14.7800
High
14.7800
Volumen
95
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 202020212022202320242025 TTM

Intellia Therapeutics Inc

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

Noticias